Effect of Cisplatin on Hemostasis in Experimental Animals

Abstract

<jats:p><jats:bold>Introduction.</jats:bold> Thrombotic complications caused by the tumor and consequences of its treatment are the leading causes of death in cancer patients. The development of a model for the pathology of hemostasis, in particular the excessive pathological clot formation, in the laboratory animals receiving antitumor agents, could help find new pharmacological methods for correcting hemostatic disorders.</jats:p><jats:p><jats:bold>The purpose of the study</jats:bold> was to study the effect of cisplatin on the blood coagulation system in mice and rats.</jats:p><jats:p><jats:bold>Results</jats:bold>. An experiment using outbred mice showed that the levels of PT-INR and aPTT were decreased and the level of fibrinogen was increased on day 10 after administration of cisplatin in the maximum tolerated dose of 10 mg/kg. A significant decrease in the PT-INR and aPTT levels was observed on day 15 after cisplatin injection only in female mice. The cisplatin injection at a dose of 4 mg/kg resulted in a decrease in the PT-INR, and aPTT levels and an increase in fibrinogen concentration on day 10. In rats, a significant decrease in the PT and aPTT levels was observed in both females and males on day 15 after cisplatin injection.</jats:p><jats:p><jats:bold>Conclusion</jats:bold>. A change in the PT and NIR, aPTT levels towards decrease and fibrinogen concentration towards increase indicates the initiation of thrombus formation. </jats:p>

Seratrodast platinum(iv) hybrids efficiently inhibit cancer-related thrombosis and metastasis phenotype in vitro and in vivo

“…12 Epidemiological investigations found that approximately 10-57% of malignant tumor patients have elevated platelets; 13 the probability of VTE occurring in cancer patients is 4-8 times higher, [14][15][16] and the risk of death from cardiovascular disease is 5-7 times higher than that of the general population. 17,18 Alcalay et al also reported that VTE incidence in colorectal cancer (CRC) patients after diagnosis was close to 5% and as high as 20% in metastatic cancer. 19 Besides, up to 37% of chemotherapy patients (especially with cisplatin) experience Raynaud's phenomenon, with 25% continuing for more than 20 years after treatment.…”